Nirogacestat Provides Rapid and Sustained Pain Reduction for Patients With Desmoid Tumors
June 4th 2023Treatment with the investigational gamma secretase inhibitor nirogacestat allowed patients with progressing desmoid tumors to experience a significant and clinically meaningful reduction in several aspects of disease-related pain when compared with placebo.
Read More
Subcutaneous Pertuzumab/Trastuzumab Combo Continues to Prove Safe, Effective in HER2+ Breast Cancer
June 1st 2023Subcutaneous delivery of fixed-dose adjuvant pertuzumab plus trastuzumab proved to have favorable tolerability, with a safety profile consistent with that seen with intravenous delivery of the regimen in patients with HER2-positive breast cancer.
Read More
Epcoritamab Approval Introduces Novel Later-line Treatment Option in R/R DLBCL
May 31st 2023Tycel Phillips, MD, discusses the significance of the FDA approval for epcoritamab in diffuse large B-cell lymphoma, key data from the EPCORE NHL-1 trial that support this approval, and how the approval of epcoritamab signals the expanding role of bispecific antibodies in this patient population.
Read More
Gastrointestinal oncology experts discuss current strategies and novel developments in gastrointestinal cancers, the role of intestinal dysbiosis and gastrointestinal carcinogenesis, germline genetic features in appendiceal cancer, and the need for anticipatory, multidisciplinary guidance in clinical practice.
Read More
AEGEAN Trial Demonstrates Benefit and Viability of Novel Perioperative Treatment Approach in NSCLC
May 19th 2023John V. Heymach, MD, PhD, expands on the efficacy of perioperative durvalumab in the AEGAN trial, the significance of this unique approach for the non–small cell lung cancer treatment paradigm, and future research examining opportunities to build on or intensify the benefit achieved with this regimen.
Read More
Omidubicel Approval Represents Key Advance for Patients With Blood Cancers Requiring Transplant
May 19th 2023Mitchell E. Horwitz, MD, expands on key efficacy and safety data supporting the FDA approval of omidubicel, the significance of this decision for the blood cancer treatment paradigm, and the need for continued investigation of the agent in non-malignant disease and other patient subgroups.
Read More
Fred Saad, MD, FRCS, expands on the relationship between PSA responses and survival outcomes in the ARASENS trial, explained the use of 0.2 ng/mL as a standard cut off for undetectable PSA within this exploratory analysis, and discussed how this study elucidates future directions for research with triplet regimens in mHSPC.
Read More
CG0070 Plus Pembrolizumab Produces Durable Responses in BCG-Unresponsive NMIBC
May 18th 2023Roger Li, MD, discusses how the synergistic mechanism of pembrolizumab plus CG0070 could address unmet needs in BCG-unresponsive NMIBC, safety and efficacy data for the combination from the CORE-001 trial, and how those data support planned research efforts for CG0070 in this space.
Read More
Epcoritamab Could Provide Active and Accessible Treatment Option for R/R LBCL
May 18th 2023Chan Cheah, MBBS, FRACP, FRCPA, DMSc, discusses key safety and efficacy data from the EPCORE NHL-1 trial that may serve to support the approval of epcoritamab in patients with relapsed or refractory large B-cell lymphoma, and highlighted ongoing research efforts seeking to further move the needle forward in this disease.
Read More
Lida A. Mina, MD, discusses the evolving role of ADCs across breast cancer subtypes, current data on the use of CDK4/6 inhibitors in HR-positive, HER2-negative breast cancer, and the increased use of genomic testing and NGS to improve the sequencing of agents in triple-negative breast cancer.
Read More
Benjamin H. Lowentritt, MD, FACS, highlights key findings from the retrospective study of second-generation ARSI use in patients with metastatic castration-sensitive prostate cancer treated in clinic and discusses several directions for future analyses of real-world outcomes in prostate cancer.
Read More
Preliminary Data Show Improved Responses with Cetuximab Plus Divarasib in KRAS G12C–mutated CRC
May 16th 2023Jayesh Desai, MBBS, FRACP, reports prior phase 1 data on the use of divarasib monotherapy in KRAS G12C–mutated CRC and early efficacy, safety, and presents pharmacokinetic data from the use of divarasib plus cetuximab from a phase 1 trial.
Read More
Ibrutinib-Containing Regimens Remain of Interest Despite Agent’s Withdrawal in MCL and MZL
May 16th 2023Thomas M. Habermann, MD, expands on previous data that supported the initial accelerated approval of ibrutinib in marginal zone lymphoma and mantle cell lymphoma, phase 3 data leading to the agent’s voluntary withdrawal, and investigations of ibrutinib and other BTK inhibitors that could significantly change the treatment landscape in mantle cell lymphoma and marginal zone lymphoma.
Read More
Proof of mechanism and safety has been established for the first-in-class bisialidase and Fc fusion protein E-602 in advanced solid tumors, supporting its continued investigation and viability of harnessing glycan-mediated immune regulation as a novel therapeutic approach in this population.
Read More
Alexander Putnam Cole, MD, discusses the importance of investigating racial and ethnic disparities in prostate cancer outcomes, key data from a comparison of cancer-specific survival according to race and treatment modality, and how these results could better inform efforts to improve access to, and quality of, patient care in this disease.
Read More
The frontline combination of ribociclib and letrozole significantly prolonged overall survival over letrozole alone in a subset of patients with hormone receptor–positive, HER2-negative advanced breast cancer who had de novo metastatic disease or late recurrence from neoadjuvant therapy, according to data from an exploratory analysis of the phase 3 MONALEESA-2 trial.
Read More
Trilaciclib Prior to Sacituzumab Govitecan Shows Early Potential in Metastatic TNBC
May 12th 2023Administration of trilaciclib followed by sacituzumab govitecan showed early signals of efficacy and may reduce the incidence of adverse effects in heavily pretreated patients with unresectable locally advanced or metastatic triple-negative breast cancer, according to preliminary results from a phase 2 study.
Read More
Adjuvant Atezolizumab and Bevacizumab Delays Recurrence in Early-Stage HCC
May 10th 2023Ahmed O. Kaseb, MD, discusses how the previous approval of atezolizumab and bevacizumab in hepatocellular carcinoma provided the impetus for the IMBrave050 study, how data from this study could support the regimen’s approval in the adjuvant setting, and how this approval could substantially improve the treatment landscape for early-stage disease.
Read More
Frontline Avelumab Maintenance Provides Prolonged Survival Benefit in Urothelial Carcinoma
May 10th 2023Shilpa Gupta, MD, discussed the significance of the phase 3 JAVELIN Bladder 100 trial in urothelial cancer, updated data on the use of avelumab maintenance therapy following first-line chemotherapy in this population, and how this research could better inform patient-provider conversations about this option in the clinic.
Read More
REGN5459 Demonstrates Early Promise in Heavily Pretreated Multiple Myeloma
May 9th 2023Attaya Suvannasankha, MD, discusses the unique mechanism of action of REGN5459, the early efficacy and safety of the immunotherapy in heavily pretreated patients with relapsed/refractory multiple myeloma, and opportunities for further exploration.
Read More
Bertrand F. Tombal, MD, PhD, explains how data on the clinically relevant drug-drug interactions and TRAEs with darolutamide, docetaxel and ADT support previously reported efficacy data from the ARASENS trial, and presents lingering questions and caveats from this trial that should be addressed through continued research.
Read More
Aumolertinib Plus SRT Elicits Responses in Intracranial Oligometastatic EGFR+ NSCLC
May 4th 2023Administration of aumolertinib until intracranial oligoprogression, followed by salvage stereotactic radiation therapy, produced central nervous system responses with acceptable tolerability in patients with intracranial oligometastatic EGFR-mutant non–small cell lung cancer.
Read More
Breadth of Biomarker Testing Continues to Inform and Guide Targeted Approaches in Lung Cancer
May 4th 2023Balazs Halmos, MD, discusses factors to consider when selecting a biomarker assay for patients with non–small cell lung cancer, emphasizes the importance of secondary testing, provides recommendations for the treatment of patients with co-mutations, and highlights ongoing or future areas of interest for research within lung cancer.
Read More
Key Trial Updates Confirm and Clarify Treatment Approaches Across Genitourinary Cancers
May 2nd 2023Matthew Galsky, MD, highlights updates in metastatic urothelial cancer treatment, as well as the evolution of PARP inhibitors and the optimal use of intensified triplet therapy in prostate cancer.
Read More